Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B

Fineline Cube Dec 21, 2025
Company Drug

SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target

Fineline Cube Dec 21, 2025
Company Deals

Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma

Fineline Cube Jun 28, 2022

China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc....

Policy / Regulatory

7th National VBP Round Venue Moved to Nanjing from Shanghai

Fineline Cube Jun 27, 2022

In a departure from previous practice, the 7th national volume-based procurement (VBP) round will not...

Company Drug

Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment

Fineline Cube Jun 27, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Ascletis Pharma Presents ASC22 Phase IIb Results for Chronic Hepatitis B at ILC 2022

Fineline Cube Jun 27, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) presented the latest results of a Phase IIb clinical...

Company Drug

Cosunter Pharma’s HBV Surface Antigen Inhibitor GST-HG121 Approved for Phase I Trial

Fineline Cube Jun 27, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced receiving approval from the ethics...

Company Deals

Sanyou Biopharmaceuticals and Dragon Sail Form Strategic Partnership for Global Biopharma Services

Fineline Cube Jun 27, 2022

China-based Sanyou Biopharmaceuticals Co., Ltd has entered into a long-term strategic partnership with compatriot firm...

Medical Device

NMPA Approves Senscure’s Cryoablation Catheter and Kangduo’s Laparoscopic Surgery System

Fineline Cube Jun 27, 2022

The National Medical Products Administration (NMPA) has approved two innovative medical devices in China: Ningbo...

Company Deals

Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline

Fineline Cube Jun 27, 2022

Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100...

Company Deals

PhenoVision Bio Secures Angel Funding for Spatial Multi-Omics Technology Platform

Fineline Cube Jun 27, 2022

Beijing-based PhenoVision Biotech, a one-stop spatial multi-omics solution provider, has reportedly secured “tens of millions”...

Company Drug

GSK Launches Nucala in China for Eosinophilic Granulomatosis with Polyangiitis

Fineline Cube Jun 27, 2022

UK pharmaceutical giant GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK) has announced the official market launch...

Company Deals

Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies

Fineline Cube Jun 27, 2022

China’s Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot...

Drug

Kexing Pharmaceutical’s Oral COVID-19 Drug SHEN26 Accepted for Clinical Trial Review

Fineline Cube Jun 24, 2022

China-based Kexing Pharmaceutical (SHA: 688136) announced that a clinical trial application for SHEN26, an oral...

Company Deals

Sunshine Guojian Pharmaceutical Signs Licensing Deal for Cipterbin ADC Development

Fineline Cube Jun 24, 2022

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...

Company Drug

Takeda Pharmaceutical’s Teduglutide Filed for Marketing Approval in China

Fineline Cube Jun 24, 2022

The Center for Drug Evaluation (CDE) website in China indicates that Japan-based Takeda Pharmaceutical Co.,...

Company Deals

Guangzhou Baiyunshan Halts Spinning-off of Guangzhou Pharmaceutical Amid HK Capital Shifts

Fineline Cube Jun 24, 2022

China-based Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) has announced the suspension of the spinning-off...

Company Drug

Frontier Biotech’s Albuvirtide Shows Promising HIV Treatment Results in Phase III Trial

Fineline Cube Jun 24, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has released Phase III trial data for albuvirtide, China’s...

Company

Organon’s China Head Shi Wang Departs to Lead Sanofi Greater China

Fineline Cube Jun 23, 2022

Women’s health specialist Organon (NYSE: OGN) announced the departure of its former China unit head...

Company Drug

Antengene Receives Australian TGA Approval for ATG-018 Clinical Trial

Fineline Cube Jun 23, 2022

China-based biopharma Antengene Corporation (HKG: 6996) has announced receiving approval from the Therapeutic Goods Administration...

Company Deals

Helixon Secures RMB 500 Million in Series A Round to Advance AI-Driven Drug Development

Fineline Cube Jun 23, 2022

Beijing-based Helixon, an artificial intelligence (AI)-empowered pharmaceutical company, has reportedly secured RMB 500 million (USD...

Company Drug

Jumbo Drug Bank’s JDB153 Enters Phase I Trial for Advanced Solid Tumors

Fineline Cube Jun 23, 2022

Data from Fineline Cube indicates that JDB153, a potential first-in-class (FIC) small-molecule inhibitor targeting Mnk...

Posts pagination

1 … 592 593 594 … 600

Recent updates

  • EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B
  • SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target
  • Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration
  • BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer
  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B

Company Drug

SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.